Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that its HiFi whole-genome ...

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

GAAP net income of $3.6 million for Q4 2024, marking a significant recovery from a net loss of $82.0 million in Q4 2023. Gain of $154.4 million from a successful debt restructuring, reducing the ...

Our preliminary revenue for the first quarter met our expectations despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry.

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the ...

PacBio has delivered its first Vega systems to Berry Genomics as part of an early access agreement aimed at developing and optimizing targeted assays for carrier, prenatal, and newborn screening in ...

Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...